Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection

被引：19
|
作者：
Pogorzelska, Joanna [1 ]
Flisiak, Robert [1 ]
机构：
[1] Med Univ Bialystok, Dept Infect Dis & Hepatol, 14 Zurawia St, PL-15540 Bialystok, Poland
来源：
CLINICAL AND EXPERIMENTAL HEPATOLOGY | 2016年 / 2卷 / 02期
关键词：
HCV; paritaprevir; ombitasvir; dasabuvir;
D O I：
10.5114/ceh.2016.60247
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin (OBV/PTV/r +/- DSV +/- RBV) is a new direct-acting antiviral (DAA) regimen which has improved efficacy of chronic hepatitis C virus (HCV) treatment significantly. OBV/PTV/r +/- DSV +/- RBV in clinical trials demonstrated sustained viral response (SVR) rates close to 100%. In this article we collected currently available data of 5726 patients for evaluation of OBV/PTV/r +/- DSV +/- RBV efficacy and safety in real-world experience. The sustained viral response rate in this large population was 97%, and it was exactly the same even in patients with liver cirrhotics. According to this meta-analysis, less than 3% of patients discontinued treatment due to adverse events.
引用
收藏
页码：34 / 37
页数：4
相关论文
共 50 条
  • [21] Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis
    Ascione, Antonio
    De Luca, Massimo
    Melazzini, Mario
    Montilla, Simona
    Trotta, Maria Paola
    Petta, Salvatore
    Puoti, Massimo
    Sangiovanni, Vincenzo
    Messina, Vincenzo
    Bruno, Savino
    Izzi, Antonio
    Villa, Erica
    Aghemo, Alessio
    Zignego, Anna Linda
    Orlandini, Alessandra
    Fontanella, Luca
    Gasbarrini, Antonio
    Marzioni, Marco
    Giannini, Edoardo G.
    Craxi, Antonio
    INFECTION, 2018, 46 (05) : 607 - 615
  • [22] Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
    Liu, Chen-Hua
    Liu, Chun-Jen
    Su, Tung-Hung
    Yang, Hung-Chih
    Hong, Chun-Ming
    Tseng, Tai-Chung
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (03) : 710 - 717
  • [23] Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage
    Talal, Andrew H.
    Dumas, Emily O.
    Bauer, Barbara
    Rejman, Richard M.
    Ocque, Andrew
    Morse, Gene D.
    Lucic, Danijela
    Cloherty, Gavin A.
    King, Jennifer
    Zha, Jiuhong
    Zhang, Hongtao
    Cohen, Daniel E.
    Shulman, Nancy
    Pawlotsky, Jean-Michel
    Hezode, Christophe
    JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (03) : 474 - 482
  • [24] Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir plus Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV
    Saab, Sammy
    Gonzalez, Yuri S.
    Huber, Caroline
    Wang, Alice
    Juday, Timothy
    LIVER INTERNATIONAL, 2016, 36 (04) : 515 - 521
  • [25] Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice
    Pineda, Juan A.
    Rivero-Juarez, Antonio
    de los Santos, Ignacio
    Collado, Antonio
    Merino, Dolores
    Morano-Amado, Luis E.
    Rios, Maria J.
    Perez-Perez, Montserrat
    Tellez, Francisco
    Palacios, Rosario
    Perez, Ana B.
    Mancebo, Maria
    Rivero, Antonio
    Macias, Juan
    HIV CLINICAL TRIALS, 2018, 19 (01): : 23 - 30
  • [26] Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1-final results of the REV1TAL study
    Lubel, John
    Strasser, Simone
    Stuart, Katherine A.
    Dore, Gregory
    Thompson, Alexander
    Pianko, Stephen
    Bollipo, Steven
    Mitchell, Joanne L.
    Fragomeli, Vincenzo
    Jones, Tracey
    Chivers, Sarah
    Gow, Paul
    Iser, David
    Levy, Miriam
    Tse, Edmund
    Gazzola, Alessia
    Cheng, Wendy
    Nazareth, Saroj
    Galhenage, Sam
    Wade, Amanda
    Weltman, Martin
    Wigg, Alan
    MacQuillan, Gerry
    Sasadeusz, Joe
    George, Jacob
    Zekry, Amany
    Roberts, Stuart K.
    ANTIVIRAL THERAPY, 2017, 22 (08) : 699 - 710
  • [27] Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin
    Manea, E. D.
    Stefan, I
    Olariu, C.
    Calina, O. C.
    Jipa, R. E.
    Hristea, A.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2018, 81 (01) : 9 - 13
  • [28] Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
    Jingjing Wu
    Peng Huang
    Haozhi Fan
    Ting Tian
    Xueshan Xia
    Zuqiang Fu
    Yan Wang
    Xiangyu Ye
    Ming Yue
    Yun Zhang
    Virology Journal, 16
  • [29] Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry
    Welzel, T. M.
    Hinrichsen, H.
    Sarrazin, C.
    Buggisch, P.
    Baumgarten, A.
    Christensen, S.
    Berg, T.
    Mauss, S.
    Teuber, G.
    Stein, K.
    Deterding, K.
    van Boemmel, F.
    Heyne, R.
    John, C.
    Zimmermann, T.
    Lutz, T.
    Schott, E.
    Hettinger, J.
    Kleine, H.
    Koenig, B.
    Hueppe, D.
    Wedemeyer, H.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (10) : 840 - 849
  • [30] Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
    Wu, Jingjing
    Huang, Peng
    Fan, Haozhi
    Tian, Ting
    Xia, Xueshan
    Fu, Zuqiang
    Wang, Yan
    Ye, Xiangyu
    Yue, Ming
    Zhang, Yun
    VIROLOGY JOURNAL, 2019, 16
12345